Ultraviolet A and photosensitivity during vemurafenib therapy

New England Journal of Medicine

Volumn 366, Issue 5, 2012, Pages 480-481

  Dummer, Reinhard ^a   Rinderknecht, Jeannine ^a   Goldinger, Simone M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SUNSCREEN; VEMURAFENIB;

ARTHRALGIA; DAILY LIFE ACTIVITY; DRUG EFFICACY; ERYTHEMA; FATIGUE; HUMAN; LETTER; PHOTOSENSITIVITY; PRIORITY JOURNAL; RADIATION PROTECTION; RASH; SKIN DEFECT; SUNBURN; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 84856582443     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1113752     Document Type: Letter

References (5)

1. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-9.
2. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
3. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive metastatic melanoma. J Clin Oncol 2011;29:Suppl:8575. abstract.
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
5. Fourtanier A, Moyal D, Seité S. Sunscreens containing the broad-spectrum UVA absorber, Mexoryl SX, prevent the cutaneous detrimental effects of UV exposure: a review of clinical study results. Photodermatol Photoimmunol Photomed 2008;24:164-74.